Literature DB >> 15456941

Caprine mucopolysaccharidosis IIID: fetal and neonatal brain and liver glycosaminoglycan and morphological perturbations.

Margaret Z Jones1, Joseph Alroy, Erinn Downs-Kelly, Rebecca E Lucas, Stacey A Kraemer, Kevin T Cavanagh, Barbara King, John J Hopwood.   

Abstract

Mucopolysaccharidosis IIID (MPS IIID) is a lysosomal storage disease associated with deficient activity of the enzyme N-acetylglucosamine 6-sulfatase (EC 3.1.6.14), a lysosomal hydrolase in the heparan sulfate glycosaminoglycan (HS-GAG) degradation pathway. In caprine MPS IIID, enzyme replacement therapy reversed early postnatal systemic but not primary or secondary central nervous system (CNS) substrate accumulations. The caprine MPS IIID large animal model system was used in this investigation to define the developmental profile of morphological and biochemical perturbations to estimate a time frame for therapeutic intervention. Light and electron microscopy were used to compare the CNS, liver, and kidney of normal +/+, MPS IIID carrier +/-, and MPS IIID-affected -/- goat kids (kids), at 60, 113-114, 128-129, and 135 d gestation (dg) of a 150-d gestational period, at birth, and at 59-64 d of postnatal (d-pn) age. In the CNS of -/- kids, morphological correlations of HS-GAG and glycolipid accumulations were evident in early differentiating neurons at 60 dg. CNS and systemic developmental, regional, and cellular differences in -/- kids at all time points included more prominent and earlier accumulation of lucent, putative HS-GAG substrates in lysosomes of meningeal and perivascular macrophages and hepatic sinusoidal cells than in CNS, hepatic, or renal parenchymal cells. The amounts and compositions of HS-GAG substrates in the brain and liver of +/+, +/-, and -/- kids were determined at 60, 65, 113-114, and 128-135 dg, at birth, and 53-78 d-pn. In the CNS of -/- kids, HS-GAG concentrations were variable and exceeded those of age-matched control tissue samples in the third but not the second trimester. In contrast, hepatic HS-GAG levels in -/- kids exceeded control values at all time points evaluated and paralleled the progressive morphological alterations. CNS and hepatic HS-GAG compositions in -/- kids were similar to each other and were more complex at all pre- and postnatal ages than those from control kids. Based on the time frame of development of CNS lesions and biochemical perturbations, prenatal therapeutic intervention in caprine MPS IIID is likely to be necessary to prevent or ameliorate substantive CNS and systemic lesions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15456941     DOI: 10.1385/JMN:24:2:277

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  44 in total

1.  Metabolic studies of glycosphingolipid accumulation in mucopolysaccharidosis IIID.

Authors:  S S Liour; M Z Jones; M Suzuki; E Bieberich; R K Yu
Journal:  Mol Genet Metab       Date:  2001-03       Impact factor: 4.797

2.  Caprine mucopolysaccharidosis-IIID: clinical, biochemical, morphological and immunohistochemical characteristics.

Authors:  M Z Jones; J Alroy; P J Boyer; K T Cavanagh; K Johnson; D Gage; J Vorro; J A Render; R S Common; R A Leedle; C Lowrie; P Sharp; S S Liour; B Levene; H Hoard; R Lucas; J J Hopwood
Journal:  J Neuropathol Exp Neurol       Date:  1998-02       Impact factor: 3.685

3.  New method for quantitative determination of uronic acids.

Authors:  N Blumenkrantz; G Asboe-Hansen
Journal:  Anal Biochem       Date:  1973-08       Impact factor: 3.365

4.  Morphological observations in the nervous system of prenatal mucopolysaccharidosis II (M. Hunter).

Authors:  C Meier; U Wismann; N Herschkowitz; A Bischoff
Journal:  Acta Neuropathol       Date:  1979-11       Impact factor: 17.088

5.  Beta-mannosidosis: prenatal biochemical and morphological characteristics.

Authors:  M Z Jones; E J Rathke; K Cavanagh; L W Hancock
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

6.  Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS.

Authors:  S Byers; T Rozaklis; L K Brumfield; E Ranieri; J J Hopwood
Journal:  Mol Genet Metab       Date:  1998-12       Impact factor: 4.797

7.  Acidic glycosaminoglycans and gangliosides in the brains from four patients with genetic mucopolysaccharidosis.

Authors:  T Ikeno; R Minami; S Tsugawa; T Nakao
Journal:  Tohoku J Exp Med       Date:  1982-07       Impact factor: 1.848

8.  N-acetylglucosamine 6-sulphatase deficiency in a Nubian goat: a model of Sanfilippo syndrome type D (mucopolysaccharidosis IIID).

Authors:  J N Thompson; M Z Jones; G Dawson; P S Huffman
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

9.  In utero injection of alpha-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: infection of multiple tissues and neonatal gene expression.

Authors:  Lisa Meertens; Yongjun Zhao; Suzana Rosic-Kablar; Liheng Li; Kin Chan; Howard Dobson; Cathy Gartley; Carolyn Lutzko; John Hopwood; Donald Kohn; Stephen Kruth; Margaret R Hough; Ian D Dubé
Journal:  Hum Gene Ther       Date:  2002-10-10       Impact factor: 5.695

10.  Prenatal mucopolysaccharidosis II (Hunter): a pathogenetic study.

Authors:  U N Wiesmann; M A Spycher; C Meier; I Liebaers; N Herschkowitz
Journal:  Pediatr Res       Date:  1980-05       Impact factor: 3.756

View more
  1 in total

1.  Ataxia is the major neuropathological finding in arylsulfatase G-deficient mice: similarities and dissimilarities to Sanfilippo disease (mucopolysaccharidosis type III).

Authors:  Björn Kowalewski; Peter Heimann; Theresa Ortkras; Renate Lüllmann-Rauch; Tomo Sawada; Steven U Walkley; Thomas Dierks; Markus Damme
Journal:  Hum Mol Genet       Date:  2014-12-01       Impact factor: 6.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.